Trial Profile

A Phase 2 Study of Glofitamab as Monotherapy or in Combination With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Glofitamab (Primary) ; Obinutuzumab (Primary) ; Pirtobrutinib (Primary) ; Polatuzumab vedotin (Primary) ; Tocilizumab (Primary)
Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Richter's syndrome
Focus Therapeutic Use

Most Recent Events

22 May 2025 Number of treatment arms are increased from 3 to 4 by the addition of one more experimental arm comprising Glofitamab, Obinutuzumab, Atezolizumab and Tocilizumab. Pirtobrutinib (Jaypirca) has been added into the drug combinations of experimental arm of B Group.
22 May 2025 Planned number of patients changed from 66 to 70.
21 Dec 2023 Planned End Date changed from 26 Oct 2032 to 15 Jan 2033.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com